



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/783,884

02/19/2004

Randy Scott

39740-0007A

2652

25213

7590

10/17/2007

HELLER EHRMAN LLP
275 MIDDLEFIELD ROAD
MENLO PARK, CA 94025-3506

EXAMINER

WOOLWINE, SAMUEL C

ART UNIT

PAPER NUMBER

1637

MAIL DATE

DELIVERY MODE

10/17/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)	
	10/783,884	SCOTT ET AL.	
	Examiner	Art Unit	
	Samuel Woolwine	1637	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 06 August 2007.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 25-44, 55-71 and 73-103 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 25-44, 55-71 and 73-103 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Status

Applicant's response submitted 8/6/2007 is acknowledged. Claims 25-44, 55-71, 73-103 are pending in the application. Claims 69, 70, 89 and 103 are withdrawn from current consideration, being drawn to a non-elected invention (see page 2, OA 02/06/2007).

The objections to the specification and to claim 72 made in OA 02/06/2007 are withdrawn in view of Applicant's amendments.

The rejections of claims 33, 55, 75-88 and 90-100 under 35 U.S.C. 112, 2nd paragraph and of claims 97-100 under 35 U.S.C. 112, 1st paragraph made in OA 02/06/2007 are withdrawn in view of Applicant's amendments. Likewise the rejection of claims 75-88 and 90-100 under 35 U.S.C. 101 are withdrawn in view of Applicant's amendments.

The rejection of claims 75-88 and 90-100 under 35 U.S.C. 102(b) over Fodor et al (US 2001/0053519 A1) is maintained for the reasons of record and reiterated below. Applicant's arguments are addressed following the rejection.

The rejection of claims 25, 27-30, 34-36 and 101 under 35 U.S.C. 102(b) over Coleclough et al (1984) is withdrawn in view of Applicant's amendment to claim 25, requiring measuring the expression of at least *two* genes.

The rejection of claims 25, 27-30 and 33-44 under 35 U.S.C. 103(a) as being unpatentable over Fodor et al (US 2001/0053519 A1) in view of Duvick (USPN 7,026,123 filed August 28, 2002, priority date August 29, 2001) is maintained for the

reasons of record and reiterated below. Applicant's arguments are addressed following the rejection.

The rejection of claims 25, 28-30, 32, 33, 36-39, 44, 55-58, 61-66 and 102 under 35 U.S.C. 103(a) as being unpatentable over Dannenberg et al (US 2001/0029018 A1) in view of Duvick (USPN 7,026,123 filed August 28, 2002, priority date August 29, 2001) is maintained for the reasons of record and reiterated below. Applicant's arguments are addressed following the rejection.

The rejection of claims 67, 68 and 71-74 under 35 U.S.C. 103(a) as being unpatentable over Dannenberg et al (US 2001/0029018 A1) in view of Duvick (USPN 7,026,123 filed August 28, 2002, priority date August 29, 2001) and further in view of Dai et al (US 2003/0224374 A1, filed June 14, 2002, priority date June 18, 2001) is maintained and extended to new claim 103 for the reasons of record and reiterated below. Applicant's arguments are addressed following the rejection.

The rejection of claims 59 and 60 under 35 U.S.C. 103(a) as being unpatentable over Dannenberg et al (US 2001/0029018 A1) in view of Duvick (USPN 7,026,123 filed August 28, 2002, priority date August 29, 2001), Dai et al (US 2003/0224374 A1, filed June 14, 2002, priority date June 18, 2001), GenBank GI:8052236 (May 22, 2000), and Buck et al (1999) is maintained for the reasons of record and reiterated below. Applicant's arguments are addressed following the rejection.

Additionally, new rejections are set forth below necessitated by Applicant's amendments.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 25-44, 75-88 and 90-101 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claims 25 and 75 are independent, and all other claims depend from one or the other. Claim 25 recites "wherein the expression of said intronic RNA sequence *has been confirmed to correlate* with the expression of an exonic mRNA sequence within said target genes", while claim 75 recites "wherein the expression of said intronic sequence *is confirmed to correlate* with the expression of a corresponding exon sequence". These phrases render the metes and bounds of the claims indefinite.

Firstly, it is unclear whether or not the claims require the active step of confirming such correlation. Therefore, the claims do not adequately apprise the public as to what constitutes infringement. As stated at MPEP 2173.02:

"In reviewing a claim for compliance with 35 U.S.C. 112, second paragraph, the examiner must consider the claim as a whole to determine whether the claim appraises one of ordinary skill in the art of its scope and, therefore, serves the notice function required by 35 U.S.C. 112, second paragraph, by providing clear warning to others as to what constitutes infringement of the patent."

Secondly, assuming the claims do not require the active step of confirming a correlation, the claims do not provide a clear demarcation of the claimed subject matter.

Art Unit: 1637

If a method described in the prior art comprises all active steps of the claim (measuring gene expression of a particular gene using an oligonucleotide comprising an intron sequence of said gene), but it was not "confirmed" at the time of filing of the instant application that a correlation between level of intron and level of a corresponding exon existed, is the claim anticipated? If someone later "confirms" such a correlation for that gene (in the prior art method) after the instant filing date, does the prior art method now anticipate? Would someone practicing the prior art method before such correlation were "confirmed" be guilty of infringement? What about performing the same method after someone else "confirmed" such a correlation?

For purposes of further examination, the examiner will assume that the claims do not require the step of "confirming", and consequently these new limitations in claims 25 and 75 will be construed as a property of the gene in the claimed method, similar to the language of claim 55, which reads "wherein the expression of the intronic RNA correlates with the expression of a corresponding exonic RNA".

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 75-88 and 90-100 are rejected under 35 U.S.C. 102(b) as being anticipated by Fodor et al (US 2001/0053519 A1).

With regard to claim 75, Fodor teaches *a method for measuring gene expression* (e.g., first sentence of paragraph [0003]) *using a plurality of polynucleotides* (see paragraph [0003]) *capable of hybridizing to target genes of interest* (any polynucleotide is “capable of hybridizing” to its complementary sequence), *wherein at least one of the said polynucleotides comprises an intron-based sequence the expression of which correlates with the expression of a corresponding exon sequence*. With regard to the *wherein* limitation, Fodor teaches an array of every possible 10-mer oligonucleotide (see figures 2-5 and Example 2, paragraphs [0122]-[0124]). Since every possible sequence of 10 nucleotides is represented on the array, the array would inherently comprise *an intron-based sequence the expression of which correlates with the expression of a corresponding gene*. Fodor also teaches detecting and identifying the polynucleotide-intronic complex at, e.g. paragraph [0081] (since every 10-mer probe inherently comprises an “intron-based” sequence; see discussion in *Response to Arguments* below).

With regard to claim 76, an intron sequence can be a dinucleotide, since the claim does not specify that all of said polynucleotides comprise *complete* or *full* intron sequences. There are 2⁴ possible dinucleotides: AA, AC, AG, AT, CA, CC, CG, CT, GA, GC, GG, GT, TA, TC, TG, and TT. The intron shown in Applicant's SEQ ID NO:1 contains each of these dinucleotides. Therefore, since each of Fodor's 10-mers must contain a dinucleotide, and all dinucleotides are “intron sequences”, Fodor's complete 10-mer array meets the limitations of the claim.

With regard to claims 77-79, Fodor's complete 10-mer array inherently comprises probes for each of the amplicons listed in figures 1A-M.

With regard to claims 80-88 and 90-92, Fodor's complete 10-mer array inherently comprises probes hybridizing to all of the genes listed in claims 80, 84, 88 and 90-92. There is no explicit definition of the term "intron-based" in the disclosure of the instant application, and as explained above, not only would each 10-mer found in any intron be represented on Fodor's array, but each 10-mer on the array would also comprise "intron sequences".

With regard to claims 93 and 94, Fodor's complete 10-mer array inherently comprises probes for each of the genes listed in figure 6.

With regard to claims 95 and 96, for any possible gene having introns and exons, Fodor's complete 10-mer array would have a probe complementary to an intron as well as a probe complementary to an exon from that gene.

With regard to claims 97-99, Fodor's complete 10-mer array would comprise probes for every possible gene. Applicant's claims 97-99 are herein relied upon as evidence that at least 150 genes exist. Regarding the limitations reciting some number of genes in a "100 μm^2 section", Fodor teaches that current photolithography can attain resolution of 1 $\mu\text{m} \times 1 \mu\text{m}$ (see last sentence of paragraph [0123]), which would allow for $100 \times 100 = 10,000$ gene (i.e. gene probes) per 100 μm^2 section.

With regard to claim 100, Fodor's complete 10-mer array contains polynucleotides immobilized on a solid surface in an array (see figures 2-5 and Example 2, paragraphs [0122]-[0124]).

Response to Arguments

Applicant's arguments filed 8/6/2007 have been fully considered but they are not persuasive. Applicant's argument rests solely on the basis that Fodor does not teach that the expression of the intron sequence "has been confirmed to correlate with the expression of a corresponding exon sequence" (page 24 of the response). This argument is not found persuasive. As discussed in the rejection of claim 75 under 35 U.S.C. 112, 2nd paragraph above, the claim does not require the step of "confirming" such a correlation, and the limitation concerning such a correlation has been construed to reflect a property of the gene being analyzed. As discussed in the rejection above, an "intron-based" sequence can be nothing more than a dinucleotide sequence found in an intron. Since Fodor teaches all possible 10-mers, and since every 10-mer would comprise at least a dinucleotide, each of Fodor's 10-mers would comprise an "intron-based" sequence. Thus, Fodor's method inherently meets the limitations of the claims.

Applicant is advised to incorporate language similar to claims 25 and 55: "polynucleotide complementary to an intronic sequence" to replace the language "comprises an intron-based sequence". While it can be argued that whichever 10-mer Fodor uses to measure gene expression inherently "comprises an intron-based sequence", a similar argument would not hold that any 10-mer used would inherently be "complementary to an intronic sequence" (even though such would be present on Fodor's complete array, he would have to teach using that particular 10-mer to measure gene expression).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 25, 27-30 and 33-44 are rejected under 35 U.S.C. 103(a) as being unpatentable over Fodor et al (US 2001/0053519 A1) in view of Duvick (USPN 7,026,123 filed August 28, 2002, priority date August 29, 2001).

With regard to claim 25, Fodor teaches *a method for measuring gene expression in a biological sample* (see paragraph [0003]), *comprising:*

(a) providing a polynucleotide complementary to a sequence within a target gene, wherein the expression of said sequence correlates with the expression of an mRNA sequence within said gene (see paragraph [0081]);

(b) hybridizing said polynucleotide to said sequence to form a polynucleotide-sequence complex (see paragraph [0081]); *and*

(c) detecting and identifying the polynucleotide-sequence complex (see paragraph [0081]). Note also that Fodor teaches a complete 10-mer array. This array would inherently provide polynucleotides complementary to all possible introns.

Note that Fodor teaches measuring gene expression for “one or more target gene(s)” (paragraph [0081]). Thus it would have been obvious to measure “at least two target genes” as claim 25 has been amended to recite.

With regard to claim 27, Fodor teaches an array of every possible 10-mer oligonucleotide (see figures 2-5 and Example 2, paragraphs [0122]-[0124]). Since every possible sequence of 10 nucleotides is represented on the array, the array would inherently comprise probes for any possible intron sequence, including intron sequences at least 50 nucleotides long.

With regard to claim 28, Fodor teaches tissue (see paragraph [0055]).

With regard to claims 29 and 30, Fodor teaches analyzing hybridization patterns of sample with cancer (see end of paragraph [0087]; cancer qualifies as a tumor tissue).

With regard to claim 33, Fodor teaches fragmenting RNA (see paragraph [0118]).

With regard to claim 34, Fodor teaches biological fluids (see paragraph [0055]).

With regard to claim 35, Fodor teaches stringent hybridization conditions (see paragraphs [0031] and [0120] for example).

With regard to claim 36, Fodor teaches quantifying (see paragraph [0121 for example]).

With regard to claim 37, Fodor teaches single-stranded oligonucleotides (see for example paragraphs [0023], [0025], [0028], [0030] and [0033]).

With regard to claim 38, Fodor teaches the nucleic acid sequences of his invention may be used as probes, primers for PCR, or ligands (see paragraph [0003]).

With regard to claims 39-42, Fodor teaches simultaneous screening of up to 100,000 different hybridizations (see paragraph [0037]). Additionally, Fodor's complete 10-mer array would comprise probes for up to 4^{10} (or 1,048,576) genes (see figures 2-5 and Example 2, paragraphs [0122]-[0124]).

With regard to claim 43, Fodor teaches probes immobilized on a solid surface (see figures 2-5 and Example 2, paragraphs [0122]-[0124]).

With regard to claim 44, Fodor's complete 10-mer array would necessarily comprise probes to every gene listed in figure 6, including probes to intron sequences from these genes.

Fodor does not teach or suggest measuring gene expression by specifically using polynucleotides complementary to intron sequences (even though Fodor's complete 10-mer array as well as other n-mer arrays taught by Fodor in paragraphs [0101]-[0103] would inherently comprise polynucleotides complementary to all possible intron sequences).

Duvick teaches detecting intron RNA and that the level of detected intron RNA would be proportional to (i.e. correlate with) the transcription rate (see column 5, last paragraph, continuing in column 6). Based on this teaching, the newly added claim limitation "wherein the expression of said intronic RNA sequence has been confirmed to correlate with the expression of an exonic mRNA sequence within said target genes" would have been obvious to the ordinary artisan.

It would also have been *prima facie* obvious to one of ordinary skill in the art at the time the invention of the instant application was made to incorporate the suggestion of Duvick (to detect gene expression by detecting intron sequences) into the general method taught by Fodor for using oligonucleotide arrays to measure gene expression. Duvick teaches that "[r]ecent data from mammalian cells indicates that intron RNAs, after splicing, persist in the cell with reasonable half-lives, contrary to what was previously thought" (column 5 line 67 through column 6 line 3). Therefore, the idea of measuring gene expression by detecting intron RNA was clearly known in the art. One would have been motivated to choose intron RNA when practicing the general method taught by Fodor, because in light of Duvick's disclosure, intron RNA sequences simply

represent equivalents of the exon RNA sequences for the purpose of detecting an RNA transcript.

Furthermore, Fodor defines mRNA for purposes of his disclosure in paragraph [0038] as follows:

"The term "mRNA" refers to transcripts of a gene. Transcripts are RNA including, for example, mature messenger RNA ready for translation, products of various stages of transcript processing. Transcript processing may include splicing, editing and degradation."

Thus Fodor's view of mRNA includes "products of various stages of transcript processing", and one of ordinary skill in the art would have known that such products include intronic sequences.

Response to Arguments

Applicant's arguments filed 8/6/2007 have been fully considered but they are not persuasive. Applicant argues on page 26 of the response that a *prima facie* showing of obviousness requires: first, a teaching or suggestion of all claim limitations; second, some suggestion or motivation to combine teachings; third, a reasonable expectation of success.

Applicant argues that the references fail to teach or suggest all of the claim limitations (penultimate paragraph, page 26 of the response). This argument is not persuasive, as Applicant has not pointed out what limitations are not taught by the combined references. Applicant discusses what Fodor allegedly does not teach (last paragraph, page 26 of the response) and what Duwick allegedly does not teach

(paragraphs 1-2, page 27). In response to applicant's arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986).

In the last paragraph on page 26 of the response, Applicant states: "Fodor, in paragraph 0038, may state that transcripts are RNA including for example mature messenger RNA ready for translation, products of various stages of transcript processing. However Fodor in Example 1, uses extracted poly(A) RNA which RNA has already been processed. Accordingly, Fodor teaches the use of already processed RNA." This argument is not persuasive. The fact that Fodor teaches a particular example of using processed RNA (i.e. poly(A) RNA) in Example 1 does not negate the fact that he also teaches transcripts to include "products of various stages of transcript processing" as stated in paragraph 0038 and Applicant's own argument. Intronic RNA is a product of RNA processing. Furthermore, this argument ignores the explicit teachings of Duvick: "[r]ecent data from mammalian cells indicates that intron RNAs, after splicing, persist in the cell with reasonable half-lives, contrary to what was previously thought" (column 5 line 67 through column 6 line 3).

Applicant argues that Duvick measuring the level of a "U-tag" inserted into a plasmid that has been placed into a host cell. Applicant seems to feel that this does not teach or suggest measuring gene expression by measuring the level of intronic sequences. This argument is not persuasive. Duvick teaches designing a U-tag into an

Art Unit: 1637

intron sequence and states: “[i]n this design, the spliced-out intron RNA would be detected at a level proportional to the transcription rate” (column 5, lines 59-67). Firstly, why can such a U-tag not be considered intronic RNA? Secondly, even if it were not, Duvick’s idea would certainly suggest that intronic RNA could be used to monitor gene expression, since it “would be detected at a level proportional to the transcription rate”. Applicant has also not explained why “measuring the level of a U-tag inserted into a plasmid which has been placed into a host cell” is not “measuring the level of target genes present in a biological sample by measuring the expression level of the intronic sequence which correlates with the exonic sequence in the target gene” (paragraph 2, page 27 of the response).

Applicant’s argument that the literature teaches away from the use of intronic RNA sequences to measure gene expression (paragraph 4, page 27 of the response) is not persuasive. The references relied upon in the rejection certainly do not teach away from the claimed combination. Furthermore, Applicant’s reliance on the disclosures of Thomas, Clement, and Padgett, which are not relied upon in the rejection, is insufficient to establish a lack of a reasonable expectation of success. Applicant states that “[t]he prevailing view is that introns are rapidly degraded and therefore, more difficult to detect than exon sequences” (citing the introductions of Thomas, Clement, and Padgett). However, the Padgett reference is from 1986, roughly 15 years earlier than the disclosures of Thomas, Clement and Duvick. Furthermore, as cited in Applicant’s argument, Thomas states “in fact, it has been shown that these introns are indeed unusually stable...in contrast to typical cellular introns that are rapidly degraded”. This

Art Unit: 1637

is enough to establish that at least some introns were stable enough to detect. The other disclosure relied upon by Applicant is Clement. Published only 1 year prior to Thomas, Clement states:

"A widely held belief is that spliced introns accumulate at low levels because they are rapidly degraded (within seconds) at their site of origin in the nucleus (14, 22). However, there is little direct evidence to support this view. The only mammalian intron whose fate and stability have been examined in detail is the IVS_{IC β 1} intron from a mouse T-cell receptor (TCR)¹- β gene. This intron is easily detectable by the relatively insensitive Northern blot procedure, despite being generated from only a modestly transcribed gene (23)." (1st full paragraph, page 16920)

"Because the Pem gene is not cell type-specific and its introns appear to be typical, we hypothesized that Pem would be a good candidate to provide information on the metabolism of mammalian introns in general." (2nd full paragraph, page 16920)

"Our analysis of the three introns in the Pem coding region revealed that they had a range of half-lives that were even longer than that of the only other previously analyzed vertebrate intron, IVS_{IC β 1}." (3rd full paragraph, page 16920)

Thus Thomas teaches that introns from the Pem gene, which appear to be typical introns, are more stable (longer half-lives) than the IVS_{IC β 1} intron, which was detectable by the "relatively insensitive Northern blot procedure". Taken in their entirety then, the disclosures of Thomas and Clement support, rather than undermine, a reasonable expectation of success in using intronic sequences to measure gene expression, as suggested by the combined teachings of Fodor and Duvick.

Moreover, Duvick teaches: "[r]ecent data from mammalian cells indicates that intron RNAs, after splicing, persist in the cell with reasonable half-lives, contrary to what was previously thought" (column 5 line 67 through column 6 line 3, emphasis provided).

Claims 25, 28-30, 32, 33, 36-39, 44, 55-58, 61-66 and 102 are rejected under 35 U.S.C. 103(a) as being unpatentable over Dannenberg et al (US 2001/0029018 A1) in view of Duvick (USPN 7,026,123 filed August 28, 2002, priority date August 29, 2001).

Dannenberg discloses a method for extracting total RNA from formalin-fixed, paraffin-embedded tumor biopsy tissue, followed by reverse transcription and real-time PCR to quantitate gene expression of specific genes.

With regard to claim 25, Dannenberg teaches *a method for measuring gene expression in a biological sample* (see paragraph [0021], for example), *comprising:*

(a) providing a polynucleotide complementary to a sequence within a target gene, wherein the expression of said sequence correlates with the expression of an mRNA sequence within said gene (see paragraph [0021] and paragraphs [0049]-[0058]; polynucleotides complementary to a target gene are listed in paragraph [0055]);

(b) hybridizing said polynucleotide to said sequence to form a polynucleotide-sequence complex (see paragraph [0054]; primers and probes in real-time PCR hybridize to their targets); *and*

(c) detecting the polynucleotide-sequence complex (see paragraph [0054]).

With regard to claims 28-30, Dannenberg teaches an example involving colon cancer tumor tissue (see Example 6, paragraphs [0088]-[0089] and figure 8).

With regard to claim 32, Dannenberg teaches extracting total RNA from formalin-fixed, paraffin-embedded tumor biopsy tissue (see for example paragraph [0021]).

With regard to claim 33, Dannenberg teaches extracting total RNA from formalin-fixed, paraffin-embedded tissue (see paragraphs [0021], [0051] and [0053]). Such RNA tends to be highly fragmented (see paragraph [0003] of instant specification).

Therefore, this limitation is considered inherent to the disclosure of Dannenberg.

With regard to claim 36, Dannenberg teaches quantitating gene expression (see Example 6, paragraphs [0088]-[0089] and figure 8).

With regard to claims 37 and 38, the PCR primers and probes listed by Dannenberg are single-stranded.

With regard to claim 39, Dannenberg measures the expression of more than one target gene (see Example 6, paragraphs [0088]-[0089] and figure 8).

With regard to claim 44, Dannenberg measures expression of TS, TP, COX2 and VEGF, all of which are listed in figure 6 of the instant application (see Example 6, paragraphs [0088]-[0089] and figure 8).

With regard to claim 55, Dannenberg teaches *a method for amplifying RNA in a fixed paraffin-embedded tissue sample representing at least one gene of interest, comprising the steps of:*

(a) *contacting DNA obtained by reverse transcription of RNA comprising intronic RNA* (see paragraphs [0052] and [0053]; Dannenberg teaches reverse transcription of total RNA with random hexamers; total RNA would include RNA comprising intronic RNA),

the expression of which correlates with the expression of a corresponding exonic RNA (To the extent that this limitation is interpreted to refer to the expression of intronic RNA correlating with expression of exonic RNA (see rejection of this claim under 35 U.S.C. 112(2) above), this limitation is inherent because the steady-state level of any intron would correlate with the steady state level of any exon from the same gene, as the two are transcribed as a unit and thus have the same rate of synthesis. The steady

Art Unit: 1637

state level of a sequence, whether intron or exon, would be determined by its rate of synthesis and its rate of degradation. Therefore, even if the intron sequence degraded more rapidly than the exon sequence, the steady state levels of intron and exon would still correlate. For example, a given intron/exon pair might have a correlation of 1:5; i.e. the steady state level of the exon is 5 times greater than the steady state level of the intron. Further evidence that levels of intron correlate with levels of exon are provided by the teachings of Duvick, discussed below.),

with at least one set of PCR primers and probe corresponding to said RNA (see paragraph [0054]); and

(b) performing PCR amplification (see paragraph [0054]).

With regard to claim 56, Dannenberg teaches PCR primers and probes designed based on unique sequences in the target genes of interest (see paragraphs [0021] and [0055]).

With regard to claim 57, Dannenberg teaches extracting total RNA (which would *represent multiple genes of interest*) from formalin-fixed, paraffin-embedded tissue (see paragraphs [0021], [0051] and [0053]). Such RNA tends to be highly fragmented (see paragraph [0003] of instant specification). Therefore, this limitation is considered inherent to the disclosure of Dannenberg.

With regard to claim 58, Dannenberg teaches contacting the sample with a pool of PCR primers and probes (see paragraphs [0054] and [0055]).

With regard to claim 61, Dannenberg teaches tissue samples which are tumor tissue biopsies (see paragraph [0049]).

With regard to claim 62, one of ordinary skill in the art would have inferred that the tissue samples were obtained from human patients based on Dannenberg's corresponding use of human cell lines (which themselves represent samples derived from biopsies of human patients; see paragraph [0048]).

With regard to claim 63, Dannenberg teaches colon cancer (see Example 6, paragraphs [0088]-[0089] and figure 8).

With regard to claim 64, Dannenberg determines the expression levels of the RNA transcripts of the genes of interest (see Example 5, paragraph [0087]).

With regard to claim 65, Dannenberg teaches correlation of differential expression of the TS gene to response to 5-FU/Leucovorin (see Example 5, paragraph [0087]).

With regard to claim 66, Dannenberg measures expression of TS, TP, COX2 and VEGF, all of which are listed in figure 6 of the instant application (see Example 6, paragraphs [0088]-[0089] and figure 8).

With regard to claim 102, Dannenberg teaches reverse transcription of total RNA extracted from formalin-fixed, paraffin-embedded tissue with random hexamers (see paragraph [0053]). Thus Dannenberg's method "uses" both intronic and exonic polynucleotide sequences (since random hexamers would comprise all possible 6-mers, including those found in intronic as well as exonic sequences).

Dannenberg does not teach:

Claim 25: *detecting a polynucleotide-intronic RNA complex* (note however that Dannenberg does teach reverse transcription of total RNA with random hexamers,

which would meet claim 25 limitations of providing a polynucleotide complementary to intronic RNA and hybridizing the polynucleotide to intronic RNA to form a polynucleotide-intronic RNA complex).

Claim 36: *quantifying the expression of intronic RNA.*

Claim 55: *contacting the sample with a set of PCR primers and probe corresponding to intronic RNA.*

Claims 56 and 58: *wherein said PCR primers and probe are designed based upon intronic RNA.*

Duvick teaches detecting intron RNA and that the level of detected intron RNA would be proportional to (i.e. correlate with) the transcription rate (see column 5, last paragraph, continuing in column 6). Based on this teaching, the newly added claim limitation "wherein the expression of said intronic RNA sequence has been confirmed to correlate with the expression of an exonic mRNA sequence within said target genes" would have been obvious to the ordinary artisan.

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention of the instant application was made to incorporate the suggestion of Duvick (to detect gene expression by detecting intron sequences) into the general method taught by Dannenberg for using PCR probes and primers to amplify RNA extracted from formalin-fixed paraffin-embedded tissue. By modifying the method of Dannenberg to use PCR primers and probes based on intron sequences, one would have arrived at the claimed invention. Duvick teaches that "[r]ecent data from mammalian cells indicates that intron RNAs, after splicing, persist in the cell with

reasonable half-lives, contrary to what was previously thought" (column 5 line 67 through column 6 line 3). Therefore, the idea of measuring gene expression by detecting intron RNA was clearly known in the art. One would have been motivated to choose intron RNA when practicing the general method taught by Dannenberg, because in light of Duvick's disclosure, intron RNA sequences simply represent equivalents of the exon RNA sequences for the purpose of detecting an RNA transcript.

Response to Arguments

Applicant's arguments filed 8/6/2007 have been fully considered but they are not persuasive. Applicant's argument, beginning at the bottom of page 28, discusses what Duvick allegedly does not teach. In addition, Applicant argues that the prevailing view was that introns are rapidly degraded and thus unsuitable for use in measuring gene expression. These are the same arguments presented for the rejection of Fodor in view of Duvick, and have already been addressed.

Claims 67, 68, 71, 73, 74 and 103 are rejected under 35 U.S.C. 103(a) as being unpatentable over Dannenberg et al (US 2001/0029018 A1) in view of Duvick (USPN 7,026,123 filed August 28, 2002, priority date August 29, 2001) as applied to claims 25, 28-30, 32, 33, 36-39, 44, 55-58, 61-66 and 102 above, and further in view of Dai et al (US 2003/0224374 A1, filed June 14, 2002, priority date June 18, 2001).

The teachings of Dannenberg and Duvick have been discussed. Dannenberg and Duvick do not teach applying the method of claim 63 to a sample of breast cancer (claims 67, 68, 71, 73 and 74) or invasive breast cancer (claims 67, 68, 73 and 74).

Dannenberg and Duvick do not teach determining whether the likelihood of long-term survival of said patient without recurrence of breast cancer has increased or decreased (claims 67-68 and 71-74). Dannenberg and Duvick do not teach normalizing expression levels of genes of interest against expression levels of all RNA transcripts (claims 68, 72 and 74). Dannenberg and Duvick do not teach “making a prognostic decision regarding cancer recurrence or response to therapy” as recited in new claim 103.

With regard to claims 67, 71 and 73, Dai teaches measuring gene expression of CEGP1 (the gene corresponding to elected SEQ ID NO:1; see paragraph [0114]: “...comparing the level of expression of the markers listed in Table 5 in a sample ...”; note CEGP1 is listed in Table 5, page 45, as NM_020974/SEQ ID NO:1844; cf Table 6, page 46: NM_020974 is CEGP1) in a sample of invasive breast cancer (Applicant does not define “invasive breast cancer”, and Dai teaches selecting samples on the basis of “primary invasive breast carcinoma”; see paragraph [0178]). CEGP1 is “a gene or gene set” recited by the claims. Furthermore, Dai teaches statistical analysis (see paragraph [0120]: “...the expression level of each of the markers can be normalized by the average expression level of all the markers...”; this constitutes a “statistical analysis”).

With regard to claims 71, 73 and new claim 103, Dai teaches determining whether the likelihood of long-term survival without the recurrence of breast cancer has increased or decreased (see for example paragraph [0114]: “...the invention provides for method of determining whether an individual afflicted with breast cancer will likely experience a relapse...”; i.e. likelihood of long-term survival without the recurrence of breast cancer has decreased).

With regard to claims 68 and 74, Dai teaches "...the expression level of each of the markers can be normalized by the average expression level of all the markers..." (see paragraph [0120]).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention of the instant application was made to apply the method suggested by the combination of Dannenberg and Duvick (i.e. the method of analyzing gene expression in a fixed, embedded tissue sample using primers/probes to intronic RNA sequences) to measuring the expression of CEGP1 in a sample of invasive breast cancer, perform statistical analysis, and render a prognosis as taught by Dai, thus arriving at the claimed invention. One would have been motivated to apply the method suggested by Dannenberg and Duvick in this way, because Dai teaches that:

"Accurate prognosis, or determination of distant metastasis-free survival could allow the oncologist to tailor the administration of adjuvant chemotherapy, with women having poorer prognoses being given the most aggressive treatment. Furthermore, accurate prediction of poor prognosis would greatly impact clinical trials for new breast cancer therapies, because potential study patients could then be stratified according to prognosis. Trials could then be limited to patients having poor prognosis, in turn making it easier to discern if an experimental therapy is efficacious." (paragraph [0010])

Response to Arguments

Applicant's arguments filed 8/6/2007 have been fully considered but they are not persuasive. Applicant's arguments rely only on the arguments presented for claims 25, 28-30, 32, 33, 36-39, 44, 55-58, 61-66 and 102. These arguments have already been addressed.

Claims 59 and 60 are rejected under 35 U.S.C. 103(a) as being unpatentable over Dannenberg et al (US 2001/0029018 A1) in view of Duvick (USPN 7,026,123 filed August 28, 2002, priority date August 29, 2001) as applied to claims 25, 28-30, 32, 33,

36-39, 44, 55-58, 61-66 and 102 above, and further in view of Dai et al (US 2003/0224374 A1, filed June 14, 2002, priority date June 18, 2001), GenBank GI:8052236 (May 22, 2000, [online], [retrieved on 2007-01-30], retrieved from the Internet: <URL: <http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?8052236:OLD03:209064>>, page numbers added by the examiner for reference), and Buck et al (1999).

The teachings of Dannenberg and Duvick have been discussed. Dannenberg and Duvick do not teach the method of claim 58 wherein said pool comprises at least SEQ ID NOS:14, 15, and 16 (the elected SEQ ID NOS from figure 2). It is noted that SEQ ID NOS:14, 15 and 16 represent primers and probes corresponding to intron sequences in the CEGP1 gene (see instant figure 2).

Dai teaches measuring gene expression of CEGP1 (the gene corresponding to elected SEQ ID NO:1)(see paragraph [0114]: "...comparing the level of expression of the markers listed in Table 5 in a sample ..."; note CEGP1 is listed in Table 5, page 45 of the published application, as NM_020974/SEQ ID NO:1844; cf Table 6, page 46 of the published application: NM_020974 is CEGP1).

GenBank GI:8052236 discloses a genomic sequence comprising CEGP1 gene, including introns. The sequences of SEQ ID NOS: 14, 15 and 16 are found within intron 1 of the CEGP1 gene disclosed by GenBank GI:8052236 (page 12). Specifically, SEQ ID NO:14 corresponds to nucleotides 19135-19152, SEQ ID NO:15 corresponds to the complement of nucleotides 19182-19205, and SEQ ID NO:16 corresponds to nucleotides 19160-19174.

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention of the instant application was made to apply the method suggested by the combination of Dannenberg and Duvick (i.e. the method of analyzing gene expression in a fixed, embedded tissue sample using primers/probes to intronic RNA sequences) to measuring the expression of CEGP1 in a sample of invasive breast cancer. One would have been motivated to do this because Dai teaches that CEGP1 is a preferred marker gene whose expression correlates with prognosis (see paragraph [0114] and Tables 5 and 6), and because Dai teaches that:

"Accurate prognosis, or determination of distant metastasis-free survival could allow the oncologist to tailor the administration of adjuvant chemotherapy, with women having poorer prognoses being given the most aggressive treatment. Furthermore, accurate prediction of poor prognosis would greatly impact clinical trials for new breast cancer therapies, because potential study patients could then be stratified according to prognosis. Trials could then be limited to patients having poor prognosis, in turn making it easier to discern if an experimental therapy is efficacious." (paragraph [0010])

It would also have been obvious to select primers and probes corresponding to SEQ ID NOS:14, 15 and 16 from the known sequence of the CEGP1 gene because the primers and probes of SEQ ID NOS:14, 15 and 16 simply represent equivalents to the probes and primers suggested by Dai for the purpose of detecting CEGP1 (see paragraphs [0145], [0146] and [0154], last sentence).

Buck expressly provides evidence of the equivalence of primers. Specifically, Buck invited primer submissions from a number of labs (39) (page 532, column 3), with 69 different primers being submitted (see page 530, column 1). Buck also tested 95 primers spaced at 3 nucleotide intervals along the entire sequence at issue, thereby testing more than 1/3 of all possible 18 mer primers on the 300 base pair sequence (see page 530, column 1). When Buck tested each of the primers selected by the methods

of the different labs, Buck found that EVERY SINGLE PRIMER worked (see page 533, column 1). Only one primer ever failed, No. 8, and that primer functioned when repeated. Further, EVERY SINGLE CONTROL PRIMER functioned as well (see page 533, column 1). Buck expressly states "The results of the empirical sequencing analysis were surprising in that nearly all of the primers yielded data of extremely high quality (page 535, column 2)." Therefore, Buck provides direct evidence that all primers would be expected to function, and in particular, all primers selected according to the ordinary criteria, however different, used by 39 different laboratories. It is particularly striking that all 95 control primers functioned, which represent 1/3 of all possible primers in the target region. This clearly shows that every primer would have a reasonable expectation of success.

Regarding the obviousness of substituting equivalents known for the same purpose, MPEP 2144.06 states: "In order to rely on equivalence as a rationale supporting an obviousness rejection, the equivalency must be recognized in the prior art, and cannot be based on applicant's disclosure or the mere fact that the components at issue are functional or mechanical equivalents." In this case, Buck clearly establishes that different primers derived from a known sequence represent equivalents in terms of functioning as a primer for that sequence.

Response to Arguments

Applicant's arguments filed 8/6/2007 have been fully considered but they are not persuasive. Applicant's arguments rely only on the arguments presented for claims 25,

28-30, 32, 33, 36-39, 44, 55-58, 61-66 and 102. These arguments have already been addressed.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Samuel Woolwine whose telephone number is (571) 272-1144. The examiner can normally be reached on Mon-Fri 9:00am-5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on (571) 272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1637

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

scw

/Young J. Kim/
Primary Examiner
Art Unit 1637
Technology Center 1600